LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.28 0.79

Buy Sell

Overview

Share price change

24h

Current

Min

1.25

Max

1.29

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Recommendations
By TipRanks
Recommendations	Sell
12 Months Forecast	+57.48% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-27M 76M
Previous open	0.49
Previous close	1.28

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 lut 2026, 23:25 UTC

Hot Stocks

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 lut 2026, 23:15 UTC

Earnings

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 lut 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 lut 2026, 23:47 UTC

Earnings

Ferrovial 4Q Net EUR197M >FER.MC

25 lut 2026, 23:45 UTC

Earnings

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 lut 2026, 23:42 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 lut 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Company's Business Operations Remain Normal >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY EPS CNY47.67 >TCOM

25 lut 2026, 23:06 UTC

Earnings

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 lut 2026, 23:01 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 lut 2026, 23:00 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

25 lut 2026, 23:00 UTC

Market Talk

Earnings

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 lut 2026, 22:56 UTC

Market Talk

Earnings

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 lut 2026, 22:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 lut 2026, 22:40 UTC

Market Talk

Earnings

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 lut 2026, 22:40 UTC

Earnings

Karoon Energy Says Search for New CFO Well Advanced

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says CFO Ray Church to Leave Company

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 lut 2026, 22:38 UTC

Earnings

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

57.48% upside

12 Months Forecast

Average 2 USD 57.48%

High 2 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.